Occurrence of unsolicited adverse events. During 7 days (Day 0 - 6) following vaccination. [clinicaltrials_resource:284e59a02b98d4b589ace4b15455daf5]
PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Occurrence of unsolicited adverse events. During 7 days (Day 0 - 6) following vaccination. [clinicaltrials_resource:284e59a02b98d4b589ace4b15455daf5]
PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
Bio2RDF identifier
284e59a02b98d4b589ace4b15455daf5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:284e59a02b98d4b589ace4b15455daf5
measure [clinicaltrials_vocabulary:measure]
Occurrence of unsolicited adverse events.
time frame [clinicaltrials_vocabulary:time-frame]
During 7 days (Day 0 - 6) following vaccination.
description
PoliorixTM will be administere ...... ry with poliomyelitis vaccine.
identifier
clinicaltrials_resource:284e59a02b98d4b589ace4b15455daf5
title
Occurrence of unsolicited adve ...... 0 - 6) following vaccination.
@en
type
label
Occurrence of unsolicited adve ...... e59a02b98d4b589ace4b15455daf5]
@en